ORBi: Detailled Reference

Article (Scientific journals)

Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?

Bottomley, A.; Thomas, R.; Van Steen, Kristel et al.

2002 • In The Lancet Oncology, 3 (3), p. 145-53

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/38466

DOI
10.1016/S1470-2045(02)00677-0

PubMed
11902500

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Bottomley_2002_Human_recombinat.pdf

Publisher postprint (459.39 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Anemia/*drug therapy/etiology; Antineoplastic Combined Chemotherapy Protocols/administration &; dosage/*adverse effects; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Epoetin Alfa/*administration & dosage; Female; Hematinics/*administration & dosage; Humans; Injections, Subcutaneous; Male; Neoplasms/*complications/diagnosis; *Quality of Life; Sensitivity and Specificity

Abstract :

[en] Over the past decade an increasing number of studies have supported the use of recombinant human erythropoietin (epoetin) in cancer patients, suggesting that it improves haemoglobin concentrations for some. There is also evidence that this treatment may lead to improvement in quality of life for cancer patients. This systematic review examines the issue. We identified and critically reviewed 13 trials. Although some of the results indicate that epoetin has positive effects on quality of life, methodological limitations inherent in most of the studies hamper interpretation of data. Evidence from this review suggests that more robust designs are required to show any significant quality-of-life benefits for cancer patients undergoing epoetin treatment.

Disciplines :

Public health, health care sciences & services

Author, co-author :

Bottomley, A.

Thomas, R.

Van Steen, Kristel ; Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique

Flechtner, H.

Djulbegovic, B.

Language :

English

Title :

Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?

Publication date :

2002

Journal title :

The Lancet Oncology

ISSN :

1470-2045

eISSN :

1474-5488

Publisher :

Elsevier Science

Volume :

3

Issue :

3

Pages :

145-53

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

2002/03/21

Available on ORBi :

since 22 May 2010

Statistics

Number of views

50 (4 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

49

Scopus citations^®
without self-citations

39

OpenCitations

44

Bibliography

Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-44.
Bernhard E. Applying quality of life principles in international cancer clinical trials. In: Spilker B (Ed). Quality of life and pharmacoeconomics in clinical trials, 2nd ed. Philadelphia: Lippincott-Raven, 1996: 693-707.
Sanders C, Egger M, Donovan J, et al. Reporting on quality of life in randomized controlled trials: bibliographic study. BMJ 1998; 317: 1191-94.
Dunphy FR, Dunleavy TL, Harrison BF, et al. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer 1997; 79: 1623-28.
Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25: 548-54.
Deniston OL, Luscombe FA, Buesching DP, et al. Effect of long-term epoietin beta therapy on the quality of life of hemodialysis patients. American Society for Artificial Internal Organs Trans 1990; 36: M157-60.
Macdougall IA. Quality of life and anemia: the nephrology experience. Semin Oncol 1998; 25 (supply 7): 39-42.
Meyer JW, Eichhorn KH, Vetter K, et al, Does recombinant human erythropoietin not only treat anemia but reduce postpartum (emotional) distress as well? J Perinat Med 1995; 23: 99-109.
Lundin AP, Delano BB, Quinn-Cefaro R. Perspectives on the improvement of quality of life with epoetin alfa therapy. Pharmacotherapy 1990; 10: 22S-26S.
Gamucci T, Thorel MF, Frasca AM, et at. Erythropoietin for the prevention of anaermia in neoplastic patients treated with cisplatin. Eur J Cancer 1993; 29A (supply 2): S13-S14.
Littlewood TJ, Bajetta E, Nortier JW, et al. Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy. results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-74.
Thatcher N. Management of chemotherapy-induced anemia in solid tumors. Semin Oncol 1998; 25 (suppl 7): 23-26.
Koeller JM. Clinical guidelines for the treatment of cancer-related anemia. Pharmacotherapy 1998; 18: 156-69.
Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995; 86; 4446-53.
Osterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythrepoetin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma: a randomized multicenter study. Blood 1996; 87: 2675-82.
Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 93: 1204-14.
Neymark N. Pharmaco-economic analysis of the use of r-HuEPO in chemotherapy-induced anaemia of cancer patients. In: Bokemeyer C, Ludwig H (Eds). ESO Scientific Updates, volume 6. Anemia and cancer. Amsterdam: Elsevier BV, 2001: 189-193.
Cella D. Factors influencing quality of life in cancer patients: anaemia and fatigue. Semin Oncol 1998; 25 (suppl 7): 43-46.
Benson K, Balducci L, Milo KM, et al. Patients' attitudes regarding out-of-hospital blood transfusion. Transfusion 1996; 36: 140-43.
Bron D. Fatigue et al. qualite de vie chez le patient cancereux. Oncologie 2000; 3: 19-22.
Cella D, Bron D. The effect of epoetin alfa on quality of life in anemic cancer patients. Cancer Pract 1999; 7: 177-82.
Brandberg Y. Assessing the impact of cancer-related anaemia on quality of life and the role of HuEPO. Med Oncol 2000; 17 (suppl 1): 523-31.
Staquet M, Berzon R, Osoba D, Machin D. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res 1996; 5: 496-502.
Abels RI. Recombinant human erythropoietin in the treatment of the anemia of cancer. Acta Haematol 1992; 87 (suppl 1): 4-11.
Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 1992; 19 (suppl 8): 29-35.
Abels R. Erythropoietin for anemia in cancer patients. Eur J Cancer 1993; 294 (suppl 2): S2-8.
Case DC, Bukowski JM, Carey RW, et al. Recombinant human erythrepoetin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993; 85: 801-06.
Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-82.
Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community. Oncol Pract J Clin Oncol 1997; 15: 1218-34.
Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998; 16: 3412-25.
Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994; 73: 2535-42.
Ludwig H, Sundal E, Pecherstorfer M, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995; 76: 2319-29.
Kurz CH, Marth CH, Windbichler G, et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 1997; 65: 461-66.
Malik IA, Khan ZK, Hakimali A, et al. The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy. JPMA J Pak Med Assoc 1998; 48: 127-31.
Glimelius B, Linn T, Hoffirian K, et al. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 1998; 16: 434-40.
Del Mastro L, Venturini M, Lionetto R, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997; 15: 2715-21.
Thatcher N, De Campos ES, Bell DR, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999; 80: 396-402.
Bottomley A. Depression in cancer patients: a literature review. Eur J Cancer Care 1998; 7: 181-91.
Young T, Maher J. Collecting quality of life data in EORTC clinical trials: what happens in practice? Psychooncology 1999; 8: 260-63.
Fayers PM, Machin D. Quality of life: assessment, analysis and interpretation. Chichester: John Wiley & Sons, 2000.
Priestman TJ, Baum M. Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1976; 1: 899-900.
Grunberg SM, Groshen S, Steingass S, et al. Comparison of conditional quality of life terminology and visual analogue scale measurements. Qual Life Res 1996; 5: 65-72.
Ringdal GI, Ringdal K. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnosis. Qual Life Res 1993; 2: 129-40.
Ringdal K, Ringdal GI, Kaasa S, et al. Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ-C30 across populations by means of the Mokken Scaling Model. Qual Life Res 1999; 8: 25-43.
Djulbegovic B, Bennett Lyman G. Violation of the uncertainty principle in conduct of randomized controlled trials (RCTs) of erythropoietin (EPO). Blood 1999; 94: 399a.
Bucquet C, Guillemin F, Briancon S. Nonspecific effects in longitudinal studies: impact on quality of life measures. J Clin Epidemiol 1996; 49: 15-20.
Koller M, Heitmann K, Kussmann J, Lorenz W. Symptom reporting in cancer patients: II, relations to social desirability, negative affect, and self-reported health behaviors. Cancer 1999; 86: 1609-20.
Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 1994; 12: 608-16.
Kong SX, Gandhi SK. Methodologic assessments of quality of life measures in clinical trials. Ann Pharmacother 1997; 31: 830-36.

Similar publications